Tumor mutation burden as emerging biomarker in non-small cell lung cancer and beyond

Tumor mutation burden (TMB) has shown to be predictive for response to immune checkpoint inhibition in several tumor entities, including non-small cell lung cancer (NSCLC) (1,2). However, implementation of TMB for treatment decision is hampered by the fact that measurement of whole exome sequencing (WES) is not feasible for clinical routine.